Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
Synonyms: desensitisation, allergen immunotherapy
During hyposensitisation the aim is to expose a patient with sensitivity to a known allergen, to progressively larger doses of the allergen so that the severity of their hypersensitive response is reduced or even abolished.
Various appraisal methods have been devised to measure efficacy.
The most common allergens administered worldwide
- Seasonal allergic hay fever not responding to anti-allergy medication but not in asthmatic patients, as this group is more likely to have a severe reaction.
- Hypersensitivity to wasp and bee venoms - asthmatics not excluded as the reaction to sting is potentially life-threatening, whereas hyposensitisation under controlled conditions would include ready access to resuscitation facilities.
Points to note regarding the use of allergen immunotherapy
- There is inadequate evidence of the benefit from desensitisation to other allergens such as house dust, house dust mite, animal danders and foods and these are thus not recommended at present.
- Allergen immunotherapy is not effective in the treatment of atopic dermatitis, urticaria, or headaches and is potentially dangerous if used for food or antibiotic allergies.
- Allergen immunotherapy (also called allergy vaccine therapy) involves the administration of gradually increasing quantities of specific allergens to patients with IgE-mediated conditions until a dose is reached that is effective in reducing disease severity from natural exposure.
- Progressive exposure to the allergen leads to IgG production rather than the IgE production which occurs in type 1 allergic responses.
- Safe administration of allergen immunotherapy requires the immediate availability of a healthcare professional capable of recognising and treating anaphylaxis, and the presence of cardiopulmonary resuscitation facilities.
- An observation period of one hour after injection is mandatory. If the patient develops any symptoms, even if mild, they need to be observed until these completely resolve.
- One study found that the use of an ultra-short course (four doses) of grass modified allergen tyrosine adsorbate monophosphoryl lipid A (MATA MPLA®) was effective.
- Patients should not be taking beta-adrenergic blocking agents or angiotensin-converting enzyme (ACE) inhibitors when receiving immunotherapy because these drugs may mask early signs and symptoms of anaphylaxis and may make the treatment of anaphylaxis more difficult.
Patients need to be referred to a specialist in immunotherapy. Diagnostic skin tests alone are unreliable and should only be used in conjunction with a detailed history of allergen exposure.
Benefits and risks
- Hyposensitisation may be effective in allergic rhinitis if sensitisation to a particular allergen can be proven.
- The benefit of hyposensitisation needs to be balanced against the significant risk of anaphylaxis, particularly in patients with asthma.
- An Australian review estimated the risk of mild effects at 1 in 1,500 injections; near-fatal anaphylaxis one per million injections and death at one in 2.5 million injections.
- Pregnant women.
- Children under five years old.
- Those taking betablockers (may render adrenaline ineffective in hypersensitivity).
- Patients on ACE inhibitors - they can develop severe anaphylactoid reactions.
These mostly relate to the site of injection - for example:
- The allergen is given subcutaneously
- Recent studies have investigated the effects of sublingual allergen administration.
Sublingual allergen administration
There have been a number of studies that have observed the effects of sublingual grass pollen. For example, a randomised, double-blind, placebo-controlled trial testing sublingual grass pollen was associated with a significant decrease in symptoms and reduced the frequency of other treatment usage, eg steroids. There were no significant adverse events associated with this product.
A preparation called Grazax® to use in immunotherapy for grass pollen allergy is now licensed in the UK. The first dose is usually administered in clinic and can then continue unsupervised. It is taken for three to four months before the pollen season and therapy should continue (for up to three years). Adverse effects have been described and include oral itching and mild swelling. Other sublingual preparations are undergoing further research in hay fever and food allergies.
One study reported that oral immunotherapy was preferred by patients and improved compliance. Another found significant improvement in quality of life outcomes.
Further reading and references
Broide DH; Immunomodulation of allergic disease. Annu Rev Med. 200960:279-91.
Rank MA, Li JT; Allergen immunotherapy. Mayo Clin Proc. 2007 Sep82(9):1119-23.
Grouin JM, Vicaut E, Jean-Alphonse S, et al; The average Adjusted Symptom Score, a new primary efficacy end-point for specific Clin Exp Allergy. 2011 Mar 7. doi: 10.1111/j.1365-2222.2011.03700.x.
Srivastava D, Arora N, Singh BP; Current immunological approaches for management of allergic rhinitis and Inflamm Res. 2009 Sep58(9):523-36. Epub 2009 Mar 31.
Dubuske L, Frew A, Horak F, et al; Ultrashort-specific immunotherapy successfully treats seasonal allergic Allergy Asthma Proc. 2011 Apr 29.
Saltoun C, Avila PC; Advances in upper airway diseases and allergen immunotherapy in 2007. J Allergy Clin Immunol. 2008 Sep122(3):481-7. Epub 2008 Aug 9.
Douglass JA, O'Hehir RE; 1. Diagnosis, treatment and prevention of allergic disease: the basics. Med J Aust. 2006 Aug 21185(4):228-33.
Weiner JM; Allergen injection immunotherapy. Med J Aust. 2006 Aug 21185(4):234.
Dahl R, Kapp A, Colombo G, et al; Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008 Feb121(2):512-518.e2. Epub 2007 Dec 26.
Summary of Product Characteristics (SPC) Grazax®; ALK-Abello Ltd, electronic Medicines Compendium, December 2013
Bonnin AJ, Zacharias DM; Sublingual immunotherapy. N Engl J Med. 2008 Aug 21359(8):869-70
Frati F, Scurati S, Puccinelli P, et al; Development of a sublingual allergy vaccine for grass pollinosis. Drug Des Devel Ther. 2010 Jul 214:99-105.
Burks AW, Laubach S, Jones SM; Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008 Jun121(6):1344-50. Epub 2008 Apr 14.
Sieber J, De Geest S, Shah-Hosseini K, et al; Medication persistence with long-term, specific grass pollen immunotherapy Curr Med Res Opin. 2011 Apr27(4):855-61. Epub 2011 Feb 16.
Wise SK, Woody J, Koepp S, et al; Quality of life outcomes with sublingual immunotherapy. Am J Otolaryngol. 2009 Sep-Oct30(5):305-11. Epub 2009 Feb 6.